共同病理改变了神经退行性疾病中海马区蛋白质积累模式
Koji Yoshida1,2,3, Shelley L Forrest1,2,4,5, Shojiro Ichimata1,2,3
1Department of Laboratory Medicine and Pathobiology and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2024
概括
神经退行性疾病在海马体中表现出明显的蛋白质沉积模式,根据亚区域和疾病类型而异. 蛋白质积累与疾病阶段达到顶峰,然后下降,受同时存在的病理的影响.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 神经病理学神经病理学
- 神经科学是一个神经科学.
背景情况:
- 关于神经退行性疾病中海马蛋白沉积模式的研究有限.
- 了解这些模式对于诊断和治疗这些疾病至关重要.
研究的目的:
- 为了研究关键蛋白质 (p-tau,Aβ,α-synuclein,pTDP-43) 在各种神经退行性疾病中的海马亚区域的分布.
- 探索蛋白质沉积,金字塔细胞密度和疾病阶段之间的关系.
- 确定共同病理对蛋白质积累模式的影响.
主要方法:
- 在海马子区域 (CA1-4,ProS,Subiculum) 评估酸化 (p-tau),粉样β (Aβ),α-synuclein 和酸化TDP-43 的面积密度.
- 每个子区域的量化金字塔细胞密度.
- 分析了166例不同神经退行性疾病的病例.
主要成果:
- 与阿尔茨海默氏症相关的p-tau在前 (ProS) 中占主导地位.
- 粉样β (Aβ) 沉积在CA1中最为突出,而α-synuclein在CA2.中最为突出.
- 蛋白质沉积密度随病理阶段的增加而增加,达到峰值,然后在晚期的阶段与金字塔细胞密度一起下降.
- 伴随性蛋白质病理显著改变了沉积模式.
结论:
- 独特的海马蛋白质积累模式是不同神经退行性疾病的特征.
- 蛋白质沉积和神经元损失遵循与疾病进展和共同病理相关的动态过程.
- 这项研究提供了海马体中蛋白质病变的全面地图.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.莱维体病是莱维体病的一种疾病.在TDP-43中.这是一种α-synuclein.氨基βββββββββββββββββββββββββ皮层骨干退行症 皮层骨干退行症在海马体内,海马体边缘主导与年龄相关的TDP-43脑病变神经病理变化酸化的酸是酸中的一种.渐进性的超核性麻.更多相关视频
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
The Proteasome
8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K


